MedPath

A pilot clinical trial to evaluate the ability of pegylate r-metHg-CSF (Pegilgrastim) to accelerate haematology recovery of patients with Non-Hodgkins Lymphoma after High-dose chemiotherapy and autologous stem cell transplantation.

Conditions
Patients with - risk Non-Hodgkin's Lymphoma in complete or partial response who underwent autologous PBPC transplantation after high-dose chemiotherapy.
MedDRA version: 6.1Level: HLTClassification code 10012819
Registration Number
EUCTR2005-004442-14-IT
Lead Sponsor
IVERSITA' DEGLI STUDI DI UDINE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: ;Secondary Objective: ;Primary end point(s):
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath